35 completed, 7 unknown, 6 terminated, 4 active not recruiting. 20 Phase 4, 15 Phase 3, 11 Phase 2, 3 Early Phase 1, 3 Phase 1.
Follow Fingolimod: new trials by email Literature Review of Fingolimod trials Research Report on Fingolimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | Biogen | 185 | 2026-11-16 | 2026-03-19 |
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | TG Therapeutics, Inc. | 240 | 2026-07-01 | 2026-10-29 |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis Ozanimod, Fingolimod, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Recruiting | Bristol-Myers Squibb | 194 | 2025-04-08 | 2026-09-10 |
| Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage Fingolimod - Intracerebral Hemorrhage | Phase 1 / Phase 2 | Unknown | Tang-Du Hospital | 40 | 2023-10-11 | 2023-10-18 |
| Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Fingolimod, Placebo - Interstitial Fibrosis, Kidney Transplant; Complications | Phase 2 | Enrolling by invitation | The Methodist Hospital Research Institute | 20 | 2022-07-28 | 2025-03-14 |
| A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) Ocrelizumab, Ocrelizumab Placebo, Fingolimod - Relapsing-remitting Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 188 | 2022-05-19 | 2026-07-15 |
| Fingolimod for Type 2 Diabetes Mellitus Fingolimod, guideline-based treatment for DM - Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | General Hospital of Shenyang Military Region | 40 | 2022-03-15 | 2026-09-10 |
| Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt Fingolimod - Relapsing-Remitting Multiple Sclerosis | Completed | Hikma Pharmaceuticals LLC | 30 | 2022-01-19 | 2024-08-23 | |
| Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Fingolimod, Ofatumumab, Siponimod - Multiple Sclerosis (MS) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 129 | 2021-10-05 | 2026-05-14 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies Diroximel Fumarate, Alemtuzumab, Fingolimod - Multiple Sclerosis | Active not recruiting | Biogen | 1178 | 2021-09-24 | 2026-10-15 | |
| Revascularization Pretreated With Fingolimod in Acute Stroke Fingolimod, placebo - Stroke | Not applicable | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2021-02-01 | 2021-01-22 |
| Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke Fingolimod, Placebo - Stroke, Inflammation | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 118 | 2021-01-15 | 2023-04-18 |
| Fingolimod in Endovascular Treatment of Ischemic Stroke Fingolimod - Stroke Inflammation | Phase 2 | Unknown | Ning Wang, MD., PhD. | 30 | 2020-11-12 | 2022-04-13 |
| Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis Fingolimod - Multiple Sclerosis | Phase 4 | Recruiting | Novartis Pharmaceuticals | 30 | 2020-10-12 | 2026-06-26 |
| Relationship Between Oral DMT Burden and Adherence in MS Cladribine, Dimethyl fumarate, Fingolimod - Multiple Sclerosis, Adherence, Medication | Unknown | Monash University | 323 | 2020-09-25 | 2022-08-31 | |
| Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage Fingolimod, Placebo, Open-label Fingolimod - Intracerebral Hemorrhage, Cerebral Edema | Early Phase 1 | Completed | Wake Forest University Health Sciences | 28 | 2020-08-07 | 2025-01-23 |
| Impact of Fingolimod Adherence on Outcomes Fingolimod - Multiple Sclerosis | Completed | Novartis Pharmaceuticals | 694 | 2020-05-18 | 2021-12-16 | |
| Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration - Breast Carcinoma | Phase 1 | Completed | Mayo Clinic | 2 | 2019-12-12 | 2023-07-21 |
| Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration - Chemotherapy-Induced Peripheral Neuropathy, Numbness | Early Phase 1 | Completed | Mayo Clinic | 2 | 2019-05-24 | 2023-09-11 |
| A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod Fingolimod - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 382 | 2017-09-19 | 2021-10-07 |
Showing 20 of 61. Sign in to see all of them.
Multiple Sclerosis (32) · Multiple Sclerosis, Relapsing-Remitting (25) · Stroke (5) · Ischemic Stroke (3) · Cerebral Hemorrhage (2) · Inflammation (2) · Neurologic Manifestations (2) · Amyotrophic Lateral Sclerosis (1) · Anxiety Disorders (1) · Astrocytoma (1) · Brain Edema (1) · Brain Injuries (1) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Demyelinating Diseases (1)
Novartis Pharmaceuticals (26) · Novartis (4) · Biogen (3) · Mayo Clinic (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Bristol-Myers Squibb (1) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (1) · General Hospital of Shenyang Military Region (1) · Heinrich-Heine University, Duesseldorf (1) · Hikma Pharmaceuticals LLC (1) · Hoffmann-La Roche (1) · Indiana University (1) · Isfahan University of Medical Sciences (1) · Karolinska Institutet (1) · Massachusetts General Hospital (1)
United States (25) · Germany (17) · Canada (13) · Italy (13) · Australia (12) · Poland (10) · Spain (10) · France (9) · United Kingdom (9) · Mexico (8) · Argentina (7) · Austria (7) · Belgium (7) · Brazil (7) · Puerto Rico (6)
Charles L Loprinzi (2) · Alan Breier, MD (1) · Amit Bar-Or, MD (1) · Anders Svenningsson, MD, PhD (1) · Anna Fogdell-Hahn, PhD (1) · Annette Langer-Gould, MD, PhD (1) · Bernd Kieseier, Prof. (1) · Christoph Heesen (1) · Ernest Butler, PhD; MD (1) · Fredrik Piehl, MD, PhD (1) · Fu-Dong Shi, MD,PhD (1)
PMID 23647445, PMID 24051419, PMID 24475777, PMID 24685276, PMID 25003359, PMID 25245812, PMID 25424122, PMID 26121423, PMID 26170105, PMID 26202811, PMID 26265273, PMID 26265274, PMID 27733070, PMID 28129749, PMID 28856176, PMID 30001923, PMID 30050529, PMID 30207920, PMID 31467033, PMID 31598139, PMID 31941953, PMID 32852530, PMID 33082194, PMID 35720286, PMID 36286605, PMID 38744460, PMID 39812825, PMID 39855661
2023 (2), P30CA015083 (2), 2017 (1), 2025 (1), UL1TR001420 (1)